Evidence map›Paper›PMID 24742266›Full record

ArticleJournal of women's health (2002)2014

Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study.

Danielle F Haley, Carol Golin, Wafaa El-Sadr, James P Hughes, Jing Wang, Malika Roman Isler, Sharon Mannheimer, Irene Kuo, Jonathan Lucas, Elizabeth DiNenno and 9 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of women's health (2002), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00995176 (The Women's HIV SeroIncidence Study), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00995176 completednot on this map

The Women's HIV SeroIncidence Study (ISIS)

TypeobservationalSponsorHIV Prevention Trials NetworkRan2009 to 2011Enrolled2,099ConditionsHIV Infections
3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Danielle F Haley1 FHI 360, Durham, North Carolina.
Carol Golin
Wafaa El-Sadr
James P Hughes
Jing Wang
Malika Roman Isler
Sharon Mannheimer
Irene Kuo
Jonathan Lucas
Elizabeth DiNenno
Jessica Justman
Paula M Frew
Lynda Emel
Anne Rompalo
Sarah Polk
Adaora A Adimora
Lorenna Rodriquez
Lydia Soto-Torres
Sally Hodder

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Institute for Clinical and Translational Research (UL1)UL1RR025005 · NCRR · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2007 to 2011
$75.8M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Emory HIV/AIDS Clinical Trials UnitUM1AI069418 · NIAID · EMORY UNIVERSITY · PI Colleen F Kelley · 2012 to 2026
$46.0M
Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6M
Intramural CDC HHS CC999999NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR001079NCRR NIH HHS RR 025747NCRR NIH HHS UL1 RR025008NCRR NIH HHS UL1 RR25005NIAID NIH HHS 5 UM1 AI069503-07NIAID NIH HHS 5UO1AI069418NIAID NIH HHS AI050410NIAID NIH HHS AI069423NIAID NIH HHS AI069465NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS U01-AI068613NIAID NIH HHS U01 AI069418NIAID NIH HHS UM1-AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI069418NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069470NICHD NIH HHS K24 HD069204NIGMS NIH HHS U54 GM104942PHS HHS 5U1AL069466
6 · The paper itself

Abstract

backgroundThe challenge of identifying and recruiting U.S. women at elevated risk for HIV acquisition impedes prevention studies and services. HIV Prevention Trials Network (HPTN) 064 was a U.S. multisite, longitudinal cohort study designed to estimate HIV incidence among women living in communities with prevalent HIV and poverty. Venue-based sampling (VBS) methodologies and participant and venue characteristics are described.

methodsEligible women were recruited from 10 U.S. communities with prevalent HIV and poverty using VBS. Participant eligibility criteria included age 18-44 years, residing in a designated census tract/zip code, and self-report of at least one high-risk personal and/or male sexual partner characteristic associated with HIV acquisition (e.g., incarceration history). Ethnography was conducted to finalize recruitment areas and venues.

resultsEight thousand twenty-nine women were screened and 2,099 women were enrolled (88% black, median age 29 years) over 14 months. The majority of participants were recruited from outdoor venues (58%), retail spaces (18%), and social service organizations (13%). The proportion of women recruited per venue category varied by site. Most participants (73%) had both individual and partner characteristics that qualified them for the study; 14% were eligible based on partner risk only.

conclusionVBS is a feasible and effective approach to rapidly recruit a population of women at enhanced risk for HIV in the United States. Such a recruitment approach is needed in order to engage women most at risk and requires strong community engagement.

Indexed as

Patient SelectionResearch DesignAdolescentAdultFeasibility StudiesFemaleHIV InfectionsHumansIncidenceLongitudinal StudiesMalePovertyPrevalenceResidence CharacteristicsRisk-TakingSexual Partners

Identifiers

PMID24742266
PMCPMC4046355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.